
These include 70,75,010 HCWs (1st dose), 37,39,478 HCWs (2nd dose), 67,92,319FLWs (1st dose) and 3,25,972 FLWs (2nd dose), 7,01,80 9beneficiaries aged more than 45 years with specific co-morbidities (1st dose) and 43,74,145 beneficiaries aged more than 60 years.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3brv9Iy
via
IFTTT
0 comments:
Post a Comment